- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06711887
루푸스 신염 환자를 대상으로 연구 치료 중단 여부에 관계없이 Ianalumab의 유효성 및 안전성에 대한 제3상 연장 연구(SIRIUS-LN 연장) (SIRIUS-LN ext)
CVAY736K12301 핵심 연구(SIRIUS-LN 연장)에서 연구 치료를 완료한 루푸스 신염 성인 참가자를 대상으로 연구 치료 중단 유무에 관계없이 Ianalumab의 유효성과 안전성을 평가하기 위한 공개 연장 연구(SIRIUS-LN 연장)
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety
- after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the SIRIUS-LN core study, and
- of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.
연구 개요
상세 설명
The SIRIUS-LN extension study is an up to 6-year open-label extension study for participants who have completed the treatment periods (blinded Treatment Period-1 and blinded Treatment Period-2) of the SIRIUS-LN core study on double-blind or open-label study treatment.
Investigators will use their clinical judgment to decide if it is beneficial for participants to continue with the extension study. In this extension study participants who achieve CRR or PRR status at Week 140 will be withdrawn from study treatment and will maintain the SoC medication as required. These up to 6 additional years in the extension study will allow to measure sustained remission, flares and safety off-study treatment. However, in the event of renal flares during the extension study, these participants who withdraw study treatment will have the option to receive open-label ianalumab.
연구 유형
등록 (추정된)
단계
- 3단계
확장된 액세스
연락처 및 위치
연구 연락처
- 이름: Novartis Pharmaceuticals
- 전화번호: 1-888-669-6682
- 이메일: novartis.email@novartis.com
연구 연락처 백업
- 이름: Novartis Pharmaceuticals
- 전화번호: +41613241111
- 이메일: novartis.email@novartis.com
연구 장소
-
-
-
Guatemala City, 과테말라, 01010
- 모병
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, 과테말라, 01011
- 모병
- Novartis Investigative Site
-
-
Departamento de Quetzaltenango
-
Quetzaltenango, Departamento de Quetzaltenango, 과테말라, 09001
- 모병
- Novartis Investigative Site
-
-
-
-
-
Taichung, 대만, 40447
- 모병
- Novartis Investigative Site
-
-
-
-
-
Seoul, 대한민국, 06591
- 모병
- Novartis Investigative Site
-
Seoul, 대한민국, 03722
- 모병
- Novartis Investigative Site
-
Seoul, 대한민국, 04763
- 모병
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, 대한민국, 16499
- 모병
- Novartis Investigative Site
-
-
-
-
-
Bucharest, 루마니아, 022328
- 모병
- Novartis Investigative Site
-
-
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, 말레이시아, 50586
- 모병
- Novartis Investigative Site
-
-
Sarawak
-
Sibu, Sarawak, 말레이시아, 96000
- 모병
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City, 멕시코, 68020
- 모병
- Novartis Investigative Site
-
Querétaro, 멕시코, 76070
- 모병
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, 멕시코, 37160
- 모병
- Novartis Investigative Site
-
-
-
-
New York
-
Orchard Park, New York, 미국, 14127
- 모병
- Circuit Clinical
-
수석 연구원:
- Isha Gupta
-
연락하다:
- Gabriella Demelo
- 이메일: gdemelo@circuitclinical.com
-
-
-
-
VNM
-
Ho Chi Minh City, VNM, 베트남, 700000
- 모병
- Novartis Investigative Site
-
-
-
-
Espírito Santo
-
Vitória, Espírito Santo, 브라질, 29055-450
- 모병
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 40150-150
- 모병
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, 브라질, 30150-221
- 모병
- Novartis Investigative Site
-
-
Pernambuco
-
Recife, Pernambuco, 브라질, 50740-900
- 모병
- Novartis Investigative Site
-
-
São Paulo
-
Santo André, São Paulo, 브라질, 09090-790
- 모병
- Novartis Investigative Site
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Novartis Investigative Site
-
-
-
-
-
Singapore, 싱가포르, 169608
- 모병
- Novartis Investigative Site
-
-
Singapore
-
Singapore, Singapore, 싱가포르, 308433
- 모병
- Novartis Investigative Site
-
-
-
-
-
Beijing, 중국, 100034
- 모병
- Novartis Investigative Site
-
Chongqing, 중국, 400038
- 모병
- Novartis Investigative Site
-
Guangzhou, 중국, 510280
- 모병
- Novartis Investigative Site
-
Guangzhou, 중국, 510080
- 모병
- Novartis Investigative Site
-
Shanghai, 중국, 200080
- 모병
- Novartis Investigative Site
-
Shanghai, 중국, 200040
- 모병
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510000
- 모병
- Novartis Investigative Site
-
Shantou, Guangdong, 중국, 515000
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Shenzhen, Guangdong, 중국, 518037
- 모병
- Novartis Investigative Site
-
-
Guangxi
-
Liuzhou, Guangxi, 중국, 545005
- 모병
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, 중국, 430060
- 모병
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, 중국, 130041
- 모병
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, 중국, 110004
- 모병
- Novartis Investigative Site
-
-
Shandong
-
Binzhou, Shandong, 중국, 256603
- 모병
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, 중국, 315016
- 모병
- Novartis Investigative Site
-
-
-
-
-
Olomouc, 체코, 779 00
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Prague, 체코, 128 00
- 모병
- Novartis Investigative Site
-
-
-
-
Antioquia
-
Medellín, Antioquia, 콜롬비아, 050001
- 모병
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, 콜롬비아, 080020
- 모병
- Novartis Investigative Site
-
-
-
-
-
Bangkok, 태국, 10400
- 모병
- Novartis Investigative Site
-
Bangkok, 태국, 10330
- 모병
- Novartis Investigative Site
-
Bangkok, 태국, 10700
- 모병
- Novartis Investigative Site
-
Chiang Mai, 태국, 50200
- 모병
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, 태국, 90110
- 모병
- Novartis Investigative Site
-
-
-
-
-
Grenoble, 프랑스, 38043
- 모병
- Novartis Investigative Site
-
-
-
-
-
Budapest, 헝가리, 1097
- 모병
- Novartis Investigative Site
-
-
-
-
-
Tuenmen, 홍콩, 999077
- 모병
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed informed consent prior to participation in the extension study.
- Participants must have participated in the SIRIUS-LN core study and must have completed the entire treatment up to Week 144 on double-blind or open label study treatment.
Exclusion Criteria:
- Use of prohibited therapies
- Pregnant or nursing (lactating) women.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Study Treatment Withdrawal (cohort 1)
(Cohort 1): Study Treatment-Withdrawal group. Participants who received blinded study treatment in the core study and achieve CRR or PRR at Week 140 in the core study will enter the extension study and discontinue study treatment while maintaining standard of care (SoC) medication, as required. If renal flare criteria are met, participants will be eligible to receive open-label ianalumab. |
|
|
실험적: Open-Label Ianalumab (cohort 2)
(Cohort 2): Open-Label Ianalumab group: Participants who received blinded study treatment throughout the core study and did not achieve CRR or PRR at Week 140 of the core study, or who had switched to open-label ianalumab during the core study, will be eligible or will continue to receive open-label ianalumab in the extension study. |
Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cohort 1: Time to renal flare, increase in immunosuppressive medication, or death
기간: Between Week 144E1 and EOS (up to Week 456)
|
Cohort 1: To estimate the time to renal flare, increase in immunosuppressive medication, or death following study treatment withdrawal in participants who completed the SIRIUS-LN core study on double-blind treatment and achieved CRR or PRR at Week 140 of the core study |
Between Week 144E1 and EOS (up to Week 456)
|
|
Cohort 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
기간: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cohort 2: Incidence and titer of anti-ianalumab antibodies in serum (ADA assay)
기간: from Week 144E1 up to Week 456
|
To assess immunogenicity to ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 2: Ianalumab concentration in serum using a validated ELISA
기간: from Week 144E1 up to Week 456
|
To assess pharmacokinetics of ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
기간: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- CVAY736K12301E1
- 2024-515280-60-00 (기타 식별자: EU CTR)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .